Skip to main content

Lonhala Magnair Side Effects

Generic name: glycopyrrolate

Medically reviewed by Last updated on Mar 14, 2024.

Note: This document contains side effect information about glycopyrrolate. Some dosage forms listed on this page may not apply to the brand name Lonhala Magnair.

Applies to glycopyrrolate: oral solution, oral tablet, oral tablet disintegrating. Other dosage forms:

Serious side effects of Lonhala Magnair

Along with its needed effects, glycopyrrolate (the active ingredient contained in Lonhala Magnair) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking glycopyrrolate:

More common

Less common

Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking glycopyrrolate:

Other side effects of Lonhala Magnair

Some side effects of glycopyrrolate may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to glycopyrrolate: compounding powder, inhalation capsule, inhalation solution, injectable solution, intravenous solution, oral solution, oral tablet, oral tablet disintegrating.


Very common (10% or more): Dry mouth (40%), vomiting (40%), constipation (35%)

Frequency not reported: Abdominal distension, abdominal pain, stomach discomfort, chapped lips, flatulence, retching, dry tongue[Ref]


Very common (10% or more): Flushing (30%)

Frequency not reported: Heart rate increase, pallor[Ref]

Nervous system

Very common (10% or more): Headache (15%)

Frequency not reported: Convulsion, dysgeusia, nystagmus

Postmarketing reports: Loss of taste[Ref]


Very common (10% or more): Urinary retention (15%)

Postmarketing reports: Suppression of lactation[Ref]


Very common (10% or more): Sinusitis (15%), upper respiratory tract infection (15%)

Frequency not reported: Pneumonia, tracheostomy infection, urinary tract infection[Ref]


Very common (10% or more): Nasal congestion (30%)

Frequency not reported: Increased viscosity of bronchial secretion, nasal dryness[Ref]


Frequency not reported: Irritability, agitation, restlessness, abnormal behavior, aggression, crying, impulse control disorder, moaning, mood altered[Ref]


Frequency not reported: Dry skin, pruritus, rash[Ref]


Frequency not reported: Dehydration[Ref]


Frequency not reported: Pain[Ref]

Frequently asked questions


1. Product Information. Cuvposa (glycopyrrolate). Shionogi USA Inc. 2010.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.